NCT04971226 2026-03-10
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
Clinical Trials
50 trialsNCT04877522 2026-03-06
Asciminib Roll-over Study
Novartis
Phase 4 Recruiting
NCT06645886 2025-12-10
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
Kumquat Biosciences Inc.
Phase 1 Recruiting
NCT04126681 2025-03-03
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
Ascentage Pharma Group Inc.
Phase 2 Completed
NCT04580121 2024-06-03
A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
Hoffmann-La Roche
Phase 1 Completed
NCT02081378 2024-03-18
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
Novartis
Phase 1 Completed
NCT03625388 2023-09-22
Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hikma Pharmaceuticals LLC
Phase 2 Completed
NCT01593254 2023-06-22
DASCERN
Bristol-Myers Squibb
Phase 2 Completed
NCT00529763 2023-05-08
Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects
Bristol-Myers Squibb
Phase 2 Completed
NCT02297139 2023-05-06
Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib
Bristol-Myers Squibb
Phase 2 Completed
NCT01850004 2022-11-03
DASFREE
Bristol-Myers Squibb
Phase 2 Completed
NCT04835584 2022-03-21
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Kartos Therapeutics, Inc.
Phase 1/2 Recruiting
NCT01460160 2021-12-08
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
Bristol-Myers Squibb
Phase 2 Completed
NCT04925141 2021-06-14
A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4 Completed
NCT02750514 2021-03-22
FRACTION-Lung
Bristol-Myers Squibb
Phase 2 Terminated
NCT02923986 2020-05-28
Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
Bio-Path Holdings, Inc.
Phase 1/2 Withdrawn
NCT02011945 2020-03-18
A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
Bristol-Myers Squibb
Phase 1 Completed
NCT03079505 2019-01-23
DANIN
Hamad Medical Corporation
Phase 3 Terminated
NCT01357655 2017-03-14
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
Bristol-Myers Squibb
Phase 2 Terminated
NCT00560352 2017-03-13
Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma
Bristol-Myers Squibb
Phase 1 Terminated
NCT00481247 2017-02-15
DASISION
Bristol-Myers Squibb
Phase 3 Completed
NCT01660906 2016-11-22
Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
Bristol-Myers Squibb
Phase 4 Completed
NCT00744497 2016-10-17
READY
Bristol-Myers Squibb
Phase 3 Completed
NCT00123474 2016-08-25
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
Bristol-Myers Squibb
Phase 3 Completed
NCT00560391 2016-08-04
Dasatinib in Combination With Revlimid (and Dexamethasone)
Bristol-Myers Squibb
Phase 1 Completed
NCT01218477 2016-06-17
Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00754325 2016-05-26
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
Bristol-Myers Squibb
Phase 2 Completed
NCT01395017 2016-04-08
LAPC
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2 Completed
NCT00324077 2016-02-17
Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase
Bristol-Myers Squibb
Phase 1 Withdrawn
NCT00349518 2016-02-17
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
Bristol-Myers Squibb
Phase 2/3 Withdrawn
NCT00982488 2016-01-22
START rollover
Bristol-Myers Squibb
Phase 2 Completed
NCT00452673 2015-03-24
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer
Bristol-Myers Squibb
Phase 1 Completed
NCT00500006 2015-01-30
A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00123487 2014-11-03
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
Bristol-Myers Squibb
Phase 3 Completed
NCT00439270 2014-03-28
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00320190 2013-10-30
Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib
Bristol-Myers Squibb
Phase 2 Terminated
NCT00385580 2013-04-30
Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT00767520 2013-02-28
Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT00948389 2012-08-31
Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT00978731 2011-04-28
Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study
Bristol-Myers Squibb
Phase 1 Completed
NCT00371345 2011-04-26
Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT00099606 2011-04-19
Phase I (PH I) Mad Refractory Solid Tumor Study
Bristol-Myers Squibb
Phase 1 Completed
NCT00101647 2011-04-15
Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia
Bristol-Myers Squibb
Phase 2 Completed
NCT00101595 2011-04-14
Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Bristol-Myers Squibb
Phase 2 Completed
NCT00162214 2011-04-14
Study of Dasatinib in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Terminated
NCT00482703 2010-12-17
A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
Bristol-Myers Squibb
Phase 1/2 Completed
NCT01030718 2010-12-14
Rollover Study of BMS-354825 in Patients With CML and Ph+ALL
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00101816 2010-08-10
Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate
Bristol-Myers Squibb
Phase 2 Completed
NCT00103844 2010-08-10
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
Bristol-Myers Squibb
Phase 2 Completed
NCT00362466 2009-11-20
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
Bristol-Myers Squibb
Phase 3 Terminated